These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19212020)

  • 1. Use of enoxaparin in emergency room for improving outcomes of primary percutaneous coronary interventions for acute myocardial infarction.
    Abhyankar AD; Pothiawala SE; Kazi GJ; Jha MJ; Petrolwala M
    Indian Heart J; 2008; 60(1):39-44. PubMed ID: 19212020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI.
    Carnendran L; Borkowski R; Markabawi B; Warner MF
    J Invasive Cardiol; 2003 May; 15(5):235-8. PubMed ID: 12730628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study.
    Zhang Q; Zhang RY; Qiu JP; Jin HG; Zhang JF; Wang XL; Jiang L; Liao ML; Hu J; Ding FH; Zhang JS; Shen WF
    Chin Med J (Engl); 2009 Mar; 122(6):636-42. PubMed ID: 19323926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
    Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
    Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
    Cohen M; Levine GN; Pieper KS; Lan L; Antman EM; Aylward PE; White HD; Kleiman NS; Califf RM; Mahaffey KW;
    Catheter Cardiovasc Interv; 2010 May; 75(6):928-35. PubMed ID: 20432399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of anticoagulants in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: a potential role for enoxaparin.
    Christy GW
    J Invasive Cardiol; 2008 Nov; 20(11):615-21. PubMed ID: 18987403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention.
    Chen WH; Lau CP; Lau YK; Ng W; Lee PY; Yu CM; Ma E
    J Invasive Cardiol; 2002 Aug; 14(8):439-42. PubMed ID: 12147872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].
    Dudek D; Zymek P; Bartuś S; Dubiel JS
    Przegl Lek; 2001; 58(6):484-6. PubMed ID: 11816736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of outcomes and safety of "facilitated" versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    McKay RG; Dada MR; Mather JF; Mennet RR; Murphy DJ; Maloney KW; Hirst JA; Kiernan FJ
    Am J Cardiol; 2009 Feb; 103(3):316-21. PubMed ID: 19166682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
    Aslam MS; Sundberg S; Sabri MN; Cooke D; Lakier JB
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):187-90. PubMed ID: 12357518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of no flow/slow reflow phenomenon in primary PCI by Nicorandil.
    J E; Juneja MS; George T; Sr R; V V; Ak B; Kalyani S; Pandurangi UM; Latchumanadhas K; S MA
    Indian Heart J; 2007; 59(3):246-9. PubMed ID: 19124934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
    Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary PCI for ST-segment elevation myocardial infarction in a patient treated with subcutaneous enoxaparin utilizing point-of-care Enox test.
    Veerappan B; Latif F; Patibandla S; Hennebry T; Ghani M; Saucedo J; Schechter E; Sadanandan S
    J Invasive Cardiol; 2003 May; 15(5):4p following A16. PubMed ID: 12784820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Brener SJ; Westerhout CM; Fu Y; Todaro TG; Moliterno DJ; Wagner GS; Granger CB; Armstrong PW;
    Am Heart J; 2009 Nov; 158(5):755-60. PubMed ID: 19853693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The significance of admission hs-CRP in patients undergoing primary percutaneous intervention for acute myocardial infarction].
    Cağli KE; Topaloğlu S; Aras D; Günel EN; Ozlü MF; Uygur B; Baysal E; Sen N
    Turk Kardiyol Dern Ars; 2009 Jan; 37(1):19-25. PubMed ID: 19225249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.